Skip to main content
All targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug Type Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Cytotoxicity Cytotoxicity Type Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
UNKNOWN NCT05724732 Patient-specific tumor neoantigen peptide presented by HLA class I (peptide–HLA complex) antigen recognition GT201 RELEVANT_DRUG C200139 TUMOR INFILTRATING LYMPHOCYTES Cellular Therapy Autologous ex vivo–expanded tumor-infiltrating lymphocyte (TIL) cell therapy enriched for tumor-reactive T cells; mediates anti-tumor activity via TCR recognition and cytotoxic mechanisms (perforin/granzyme) with cytokine secretion. Autologous ex vivo–expanded tumor-infiltrating T cells that retain native TCRs to recognize patient-specific tumor antigens and mediate anti-tumor effects via cytotoxic granule release (perforin/granzyme) and cytokine secretion, leading to direct tumor-cell killing and immune amplification. YES DIRECT Infused autologous TILs recognize the neoantigen peptide–HLA class I complex via their native TCRs and directly kill target cells through perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis), with supportive cytokine effects. Solid Tumor CANCER Tissue Solid Tumors Solid Tumors manual_review_required
UNKNOWN NCT05724732 Patient-specific tumor-associated self-antigen peptide presented by HLA class I (peptide–HLA complex) antigen recognition GT201 RELEVANT_DRUG C200139 TUMOR INFILTRATING LYMPHOCYTES Cellular Therapy Autologous ex vivo–expanded tumor-infiltrating lymphocyte (TIL) cell therapy enriched for tumor-reactive T cells; mediates anti-tumor activity via TCR recognition and cytotoxic mechanisms (perforin/granzyme) with cytokine secretion. Autologous ex vivo–expanded tumor-infiltrating T cells that retain native TCRs to recognize patient-specific tumor antigens and mediate anti-tumor effects via cytotoxic granule release (perforin/granzyme) and cytokine secretion, leading to direct tumor-cell killing and immune amplification. YES DIRECT Native TCRs on infused TILs recognize the patient-specific peptide–HLA class I complex and induce target-cell death via cytotoxic granule release (perforin/granzyme–mediated apoptosis), with possible Fas/FasL signaling. Solid Tumor CANCER Tissue Solid Tumors Solid Tumors manual_review_required
UNKNOWN NCT05724732 Patient-specific tumor neoantigen peptide presented by HLA class II (peptide–HLA complex) antigen recognition GT201 RELEVANT_DRUG C200139 TUMOR INFILTRATING LYMPHOCYTES Cellular Therapy Autologous ex vivo–expanded tumor-infiltrating lymphocyte (TIL) cell therapy enriched for tumor-reactive T cells; mediates anti-tumor activity via TCR recognition and cytotoxic mechanisms (perforin/granzyme) with cytokine secretion. Autologous ex vivo–expanded tumor-infiltrating T cells that retain native TCRs to recognize patient-specific tumor antigens and mediate anti-tumor effects via cytotoxic granule release (perforin/granzyme) and cytokine secretion, leading to direct tumor-cell killing and immune amplification. YES DIRECT Native TCR recognition of the neoantigen–HLA class II complex on target cells triggers cytotoxic granule release (perforin/granzyme) leading to apoptosis. Solid Tumor CANCER Tissue Solid Tumors Solid Tumors manual_review_required
UNKNOWN NCT05724732 Patient-specific tumor-associated self-antigen peptide presented by HLA class II (peptide–HLA complex) antigen recognition GT201 RELEVANT_DRUG C200139 TUMOR INFILTRATING LYMPHOCYTES Cellular Therapy Autologous ex vivo–expanded tumor-infiltrating lymphocyte (TIL) cell therapy enriched for tumor-reactive T cells; mediates anti-tumor activity via TCR recognition and cytotoxic mechanisms (perforin/granzyme) with cytokine secretion. Autologous ex vivo–expanded tumor-infiltrating T cells that retain native TCRs to recognize patient-specific tumor antigens and mediate anti-tumor effects via cytotoxic granule release (perforin/granzyme) and cytokine secretion, leading to direct tumor-cell killing and immune amplification. YES DIRECT Native TCRs on the infused TILs recognize the patient-specific peptide–HLA class II complex and trigger cytotoxic granule release (perforin/granzymes), inducing apoptosis; Fas–FasL can also contribute. Solid Tumor CANCER Tissue Solid Tumors Solid Tumors manual_review_required
CD19 NCT06553872 CD19 antigen recognition Brexucabtagene autoleucel (Tecartus) RELEVANT_DRUG CAR T Cellular Therapy Autologous CD19-directed CAR T-cell therapy that redirects patient T cells to recognize and eliminate CD19-positive B cells. Autologous T cells genetically engineered to express a CD19-specific chimeric antigen receptor bind CD19 on malignant B cells, triggering T‑cell activation, proliferation, cytokine release, and cytotoxic killing of CD19‑positive cells. YES DIRECT CD19-directed CAR T cells bind CD19 on target cells and induce cytolysis via perforin/granzyme release and death-receptor (Fas/FasL) signaling. Mantle Cell Lymphoma CANCER Lymphoid Non-Hodgkin Lymphoma, B Cell Mantle Cell Lymphoma ai
Displaying 1346 - 1350 of 5381